Neoadjuvant chemoimmunotherapy has demonstrated significant benefit for resectable non-small-cell lung cancer (NSCLC) excluding known <i>EGFR/ALK</i> genetic alterations. Here, EGFR is linked to non-small cell lung carcinoma.